Aspen Aerogels, Inc. (NYSE:ASPN) Shares Bought by Barclays PLC

Barclays PLC grew its position in Aspen Aerogels, Inc. (NYSE:ASPN) by 333.8% in the third quarter, HoldingsChannel reports. The fund owned 92,302 shares of the construction company’s stock after acquiring an additional 71,024 shares during the quarter. Barclays PLC’s holdings in Aspen Aerogels were worth $2,557,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Point72 Hong Kong Ltd purchased a new position in shares of Aspen Aerogels in the 2nd quarter valued at about $84,000. nVerses Capital LLC purchased a new stake in shares of Aspen Aerogels in the second quarter valued at approximately $95,000. Quent Capital LLC purchased a new position in shares of Aspen Aerogels during the 3rd quarter valued at approximately $118,000. Point72 DIFC Ltd purchased a new position in shares of Aspen Aerogels during the 2nd quarter valued at approximately $121,000. Finally, Public Employees Retirement Association of Colorado acquired a new stake in Aspen Aerogels in the 2nd quarter valued at $145,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Aspen Aerogels Trading Down 1.2 %

Shares of ASPN stock opened at $11.90 on Wednesday. The company has a current ratio of 2.93, a quick ratio of 2.48 and a debt-to-equity ratio of 0.27. Aspen Aerogels, Inc. has a twelve month low of $10.75 and a twelve month high of $33.15. The company’s 50-day moving average price is $16.10 and its 200-day moving average price is $22.15. The stock has a market cap of $976.36 million, a price-to-earnings ratio of 1,191.19 and a beta of 2.12.

Wall Street Analysts Forecast Growth

ASPN has been the topic of several recent analyst reports. Barclays decreased their price objective on shares of Aspen Aerogels from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Piper Sandler decreased their price target on shares of Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Roth Mkm cut their price objective on Aspen Aerogels from $36.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Aspen Aerogels in a research report on Wednesday, October 16th. Finally, StockNews.com upgraded Aspen Aerogels to a “sell” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.70.

Insider Buying and Selling at Aspen Aerogels

In other news, CEO Donald R. Young sold 63,355 shares of Aspen Aerogels stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the sale, the chief executive officer now owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. The trade was a 11.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.30% of the stock is currently owned by company insiders.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.